Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

In a reversal of fortune, yesterday (9 April) the UK Court of Appeal awarded AstraZeneca (AZ) an interim injunction keeping Glenmark’s ...

Michael Tappin KC, sitting as a deputy judge of the High Court, refused to grant AstraZeneca (“AZ”) an interim injunction ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

In patients with type 2 diabetes and albuminuria, dapagliflozin leads to a significant reduction in urine ...

As heart failure patients, the TAVI population studied already is recommended to be treated with an SGLT2 inhibitor, noted ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...

Researchers found that dapagliflozin and diet combo helps nearly half of overweight adults with early type 2 diabetes achieve ...

Type 2 diabetes mellitus (T2DM) is a major public health challenge in India, with an estimated 101 million individuals ...

In the last episode, we explored the role of Dapagliflozin in specialty care settings. Moving forward, this episode delves ...